A Cheshire nurse has pleaded guilty to charges related to the illegal distribution of controlled substances, according to an announcement from David X. Sullivan, United States Attorney for the District of Connecticut.
Michele Rene Muzyka, 61, appeared before U.S. District Judge Victor A. Bolden in New Haven on January 21, 2026. She waived her right to be indicted and entered a guilty plea.
Court documents and statements indicate that between January 2024 and June 2025, Muzyka, who is an Advanced Practice Registered Nurse (APRN), unlawfully distributed amphetamines and benzodiazepines to individuals without legitimate medical need. The investigation found that during office visits, Muzyka did not conduct medical examinations or confirm conditions that would require treatment with these substances. She charged patients $200 in cash for office visits where she prescribed Schedule II and IV controlled substances. This included prescribing medication to an undercover agent posing as a Medicaid beneficiary. Although enrolled as a Medicare and Medicaid provider, Muzyka refused the undercover agent’s Medicaid plan and instead collected a $200 cash fee. Medicaid later paid $287.58 for unlawful prescriptions written for the agent.
Muzyka was arrested on June 23, 2025.
She pleaded guilty to possession with intent to distribute, distribution of, and dispensing of controlled substances. The offense carries a maximum prison term of 20 years. Muzyka is currently released on a $75,000 bond pending sentencing scheduled for April 30.
The Drug Enforcement Administration and the U.S. Department of Health and Human Services Office of Inspector General led the investigation with support from the Connecticut Department of Consumer Protection's Drug Control Division. Assistant U.S. Attorney Katherine E. Boyles is prosecuting the case.
"This investigation is being conducted by the Drug Enforcement Administration and the U.S. Department of Health and Human Services, Office of the Inspector General, with assistance from the Connecticut Department of Consumer Protection, Drug Control Division," according to the press release.
